Lipocine, Inc.
(NASDAQ : LPCN)

( )
LPCN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc -1.28%98.565.4%$171.46m
SAVACassava Sciences, Inc. -4.12%43.960.0%$168.58m
VRXValeant Pharmaceuticals International, Inc. 2.49%24.3214.1%$143.10m
CTLTCatalent, Inc. -1.29%120.892.0%$127.87m
ICLRICON plc -2.52%265.942.8%$108.47m
CPIXCumberland Pharmaceuticals, Inc. 51.20%6.940.6%$98.35m
JAZZJazz Pharmaceuticals Plc 1.04%121.512.1%$77.60m
UTHRUnited Therapeutics Corp. 1.47%188.7213.9%$72.58m
PRGOPerrigo Co. Plc 3.47%37.036.9%$66.48m
BHCBausch Health Cos., Inc. 2.49%24.320.0%$59.40m
ARGXargenx SE -1.67%278.960.0%$57.06m
ENDPEndo International Plc 0.60%5.028.5%$32.54m
CORTCorcept Therapeutics, Inc. 6.36%22.245.5%$26.01m
IRWDIronwood Pharmaceuticals, Inc. 1.91%11.199.5%$25.26m
PCRXPacira Biosciences, Inc. 2.99%54.109.8%$25.19m

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.